Theravance Biopharma
TBPH
105 hedge funds and large institutions have $1.32B invested in Theravance Biopharma in 2020 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 55 increasing their positions, 18 reducing their positions, and 18 closing their positions.
206% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 18
13% more capital invested
Capital invested by funds: $1.16B → $1.32B (+$155M)
11.36% more ownership
Funds ownership: 78.97% → 90.32% (+11%)
6% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 18
3% less funds holding
Funds holding: 108 → 105 (-3)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
47% less call options, than puts
Call options by funds: $1.52M | Put options by funds: $2.86M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$124M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$30.7M |
| 3 |
PA
Perceptive Advisors
New York
|
+$25M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$24.8M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$22.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFS
Link Fund Solutions
London,
United Kingdom
|
-$10.4M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$6.07M |
| 3 |
NM
Newtyn Management
New York
|
-$4.49M |
| 4 |
Millennium Management
New York
|
-$2.6M |
| 5 |
Morgan Stanley
New York
|
-$1.43M |
TBPH Hedge Fund Activity: Q1 2020 in Review
105 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q1 2020, worth a combined $1.32B — up 13% from $1.16B a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of TBPH and 17 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 55 added.
The largest buyer was BlackRock, adding an estimated $124M. The largest seller was Link Fund Solutions, cutting an estimated $10.4M.
- 105 institutional investors held Theravance Biopharma (TBPH) as of Q1 2020, down from 108 in Q4 2019.
- Funds reported $1.32B of Theravance Biopharma stock for Q1 2020, up 13% quarter-over-quarter.
- 17 funds opened new Theravance Biopharma positions in Q1 2020 and 18 closed out, a net change of -1 holder.
- The largest Theravance Biopharma buyer in Q1 2020 was BlackRock, an estimated $124M added.
- The largest Theravance Biopharma seller in Q1 2020 was Link Fund Solutions, an estimated $10.4M sold.
Based on aggregated 13F filings for Q1 2020.